Earnings Ahead

PLRX - Pliant Therapeutics

18.9 -0.51 -2.63

Pliant Therapeutics

Pliant Therapeutics

About

Profile


Headquarters


Intraday

High
-
Low
-

52-week

High
-
Low
-

PLRX



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Pliant Therapeutics GAAP EPS of -$0.65 beats by $0.09, revenue of $1.48M misses by $0.11M
  • Safety board recommends continuing Pliant's phase 2a trial of PLN-74809 without changes
  • Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M
  • Pliant's PLN-74809 gets FDA fast track status for liver disease
  • Pliant Therapeutics closes upsized underwritten public offering for ~$230M
  • Pliant Therapeutics prices $200M upsized stock offering
  • Pliant Therapeutics stock slides on offering of $150M of common stock
  • Pliant jumps over 100% as mid-stage trial for lung disease therapy meets key goals
  • Pliant to get $4M milestone from Novartis as fibrosis program moves into development
  • Pliant Therapeutics GAAP EPS of -$0.78 misses by $0.03, revenue of $1.25M beats by $0.2M
  • Pliant Therapeutics enters $100M loan facility to support ongoing development of PLN-74809
  • Pliant Therapeutics GAAP EPS of -$0.68 beats by $0.09, revenue of $2M misses by $0.14M
  • Pliant gets safety review nod to advance phase 2a trial of lung therapy at higher dose
  • Pliant Therapeutics EPS misses by $0.06, misses on revenue
  • MTCH, BILI and ZIOP among pre market gainers
  • Pliant Therapeutics jumps 24% on positive PLN-74809 results in Phase 2a IPF study
  • Pliant Therapeutics EPS beats by $0.03, misses on revenue
  • Pliant Therapeutics EPS misses by $0.01, misses on revenue
  • Push for Merck to work with GSK on vaccine, Ovid price target halved, and more in today's analyst action action
  • Pliant Therapeutics initiated buy at Citi noting the ‘potent’ therapeutic platform
Date Price Open High Low Vol Change ER
May 1, 2023 22.31 23.96
23.98
19.67
6.3M -26.62%
Apr 28, 2023 28.25 27.86
28.65
27.49
848K 0.88%
Apr 27, 2023 28 28.55
28.8
27.58
449K -2.36%
Apr 26, 2023 28.66 30.32
30.35
28.64
817K -5.72%
Apr 25, 2023 30.3 30.46
30.85
29.68
473K -0.86%
 
Apr 24, 2023 30.56 30.24
30.59
29.87
381K 0.69%
Apr 21, 2023 30.35 29.39
30.79
29.21
646K 3.89%
Apr 20, 2023 29.17 29.93
30.15
28.87
485K -3.43%
Apr 19, 2023 30.17 28.84
30.25
28.65
633K 3.91%
Apr 18, 2023 28.99 27.7
29.26
27.12
941K 4.45%
Apr 17, 2023 27.7 26.75
28.55
26.75
1.1M 4.33%
Apr 14, 2023 26.5 25.93
26.59
25.75
445K 1.66%
Apr 13, 2023 26.06 25.72
26.6
25.49
511K 2.53%
Apr 12, 2023 25.4 26.6
26.86
25.08
411K -3.82%
Apr 11, 2023 26.37 25.77
26.73
25.52
988K 2.65%
Apr 10, 2023 25.67 25.75
26.15
25.51
689K -0.74%
Apr 6, 2023 25.86 24.9
26.02
24.67
595K 4.06%
Apr 5, 2023 24.81 25.32
25.83
24.22
591K -2.22%
Apr 4, 2023 25.36 26.46
26.55
24.51
781K -4.42%
Apr 3, 2023 26.48 26.74
27.73
26.14
670K -0.45%
Mar 31, 2023 26.6 26.49
26.84
25.77
574K 0.23%
Mar 30, 2023 26.54 27.1
27.35
25.89
460K -2.3%
Mar 29, 2023 27.15 26.48
27.53
26.48
279K 3.09%
Mar 28, 2023 26.31 26.31
27.04
25.86
298K -0.08%
Mar 27, 2023 26.33 25.7
26.64
25.43
442K 0%